NCT05382767View on ClinicalTrials.gov

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

December 8, 2022

Study Completion Date

December 8, 2022

Conditions
Post-stroke Upper Limb Spasticity
Interventions
DRUG

CKDB-501A

Muscle Spasticity

DRUG

Botox®

Muscle Spasticity

Trial Locations (2)

Unknown

Seoul National University Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

CKD Bio Corporation

INDUSTRY